NGM282 — an engineered analogue of FGF19 — shows promise in patients with primary sclerosing cholangitis
13 April 2018, Paris, France: The fibroblast growth factor 19 (FGF19) engineered analogue, NGM282, inhibits bile acid synthesis, decreases markers of hepatic inflammation, and significantly improves markers of fibrosis in patients with primary sclerosing cholangitis (PSC), according to the results of a Phase 2, multicentre, randomized, double-blind, placebo-controlled study reported today. The study, which involved 62 patients with PSC diagnosed according to EASL criteria,7 offers hope of a new medical treatment for a condition in which effective drug therapies are currently limited.8
'Primary sclerosing cholangitis is a rare, inflammatory, cholestatic liver disease that is characterized by progressive fibrosis of the bile ducts and liver, and causes progressive liver dysfunction', explained Prof. Gideon Hirschfield from the University of Birmingham in the UK, who presented the results today at The International Liver Congress™ 2018 in Paris, France. 'Liver transplantation is effective for advanced disease, but there are currently no medical treatments that have been shown to prolong transplant-free survival'.8
NGM282 is a non-tumourigenic engineered analogue of FGF19, an endocrine gastrointestinal hormone that regulates bile acid, carbohydrate and energy homeostasis.9,10 In an animal model, NGM282 was shown to suppress the classic pathway of bile acid production, and to inhibit fatty acid synthesis and de novo lipogenesis.11 NGM282 was well tolerated in a healthy volunteer study,12 and the molecule has recently shown potential as a treatment for non-alcoholic steatohepatitis (NASH).13
The study presented today by Prof. Hirschfield randomized 62 patients with PSC and an elevated alkaline phosphatase (ALP) level (?1.5x the upper limit of normal) to receive either a daily subcutaneous injection of NGM282 at a dose of 1 mg or 3 mg, or placebo. The primary endpoint was the change in ALP from baseline to Week 12.
Although there were no significant reductions in serum ALP levels in either active treatment group compared with placebo, at Week 12 significant reductions in serum levels of alanine aminotransferase (ALT) (-40 U/L) and aspartate aminotransferase (AST) (-23 U/L) in the NGM282 3 mg/day treatment group were observed (p'We also saw significant reductions in surrogate markers of fibrogenesis in the patients who received NGM282, with reductions especially pronounced in patients with higher-risk disease (Enhanced Liver Fibrosis Score >9.8 at baseline)', said Prof. Hirschfield. 'These changes are consistent with those observed in patients with non-alcoholic steatohepatitis which were also presented at ILC this year'.
NGM282 was well tolerated in this study, with no differences in PSC-related clinical events between the NGM282 treatment groups and the placebo group. No drug-induced pruritus was observed and no neutralizing anti-drug antibodies were detected during or after treatment with NGM282. The most frequently reported adverse events amongst the NGM282-treated patients were diarrhoea, frequent stools and injection site reactions, the majority of which were mild and resolved while on treatment.
'This study provides good evidence of relevant clinical activity for NGM282 in individuals with PSC and highlights the need to explore NGM282's impact on liver fibrosis in larger studies of a longer duration', said Prof. Hirschfield. 'NGM282 seems to be a promising treatment for patients with PSC, for whom very few medical options currently exist'.
'Studies like this one are key, since they investigate possible novel treatments for PSC, a disease that currently has no effective therapies', said Prof. Marco Marzioni from the University Hospital of Ancona, Italy, and EASL Governing Board Member. 'Although this trial did not achieve fully positive results in terms of reduction of markers of disease progression, it certainly indicates that the manipulation of key molecules involved in the pathophysiology of PSC is the route to cure for our patients'.
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2018 will take place from 11¬-15 April 2018 at the Paris Convention Centre, Paris, France.
About The European Association for the Study of the Liver (EASL)
Since its foundation in 1966, this not-for-profit organization has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
For more information, please contact the ILC Press Office at:
- Email: [email protected]
- Telephone: +41 (0) 22 807 29 88
Onsite location reference
Session title: Late Breaker Session, General Hepatology
Time, date and location of session: 14. April 2018, 04:15 PM – 04:30 PM, Main Plenary
Presenter: Gideon Hirschfield, UK
Abstract: NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial (5580)
7. European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol. 2017;66(6):1265-81.
8. Dyson JK, et al. Primary sclerosing cholangitis. Lancet. 2018;doi: 10.1016/S0140-6736(18)30300-3 [Epub ahead of print].
9. Kliewer SA, et al. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015;33(3):327-31.
10. Degirolamo C, et al. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15(1):51-69.
11. Zhou M, et al. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1(10):1024-42.
12. Luo J, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med. 2014;6(247):247ra100.
13. Harrison SA, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;doi: 10.1016/S0140-6736(18)30474-4 [Epub ahead of print].